Protein discovery sheds light on autoimmune diseases

The immune system is made up of a collection of mechanisms that protect our bodies from disease and infection. But if you have an autoimmune disease, your own immune system attacks itself by mistake. Many parts of the body can be affected by these diseases, including nerves, muscles, and the endocrine and digestive systems. Autoimmune diseases are the third leading cause of morbidity and mortality in the industrialised world and are only surpassed by cancer and heart disease. Now scientists working on an EU-funded project have identified a protein, which they say will lead to new ways of understanding and treating these autoimmune diseases.

The three-year EurAPS project is funded under the 'Life Sciences, genomics and biotechnology for health' thematic area of the Sixth Framework Programme (FP6). Bringing together 16 partners from across Europe, as well as Australia and Hong Kong, the project studied a rare genetic disorder of early childhood called Autoimmune polyendocrine syndrome type I (APS-1). The findings are published in the New England Journal of Medicine.

APS-1 is a hereditary disease caused by mutations in a single gene called autoimmune regulator (AIRE). The mutation causes the immune system to produce auto-antibodies, which are then directed against one or more of the body's proteins. APS-1 patients can have a wide range of symptoms. These symptoms include hypocalcemia from the destruction of the parathyroid glands and Addison's disease from the destruction of the adrenal glands. In addition, those with the disease can also develop mucosal and skin infections with candida yeasts.

The researchers in the EurAPS project have now identified one of the proteins that comes under attack by the disease. Dubbed NALP5, this protein is the target for the immune system's attacks on the parathyroid glands. The parathyroid glands are small endocrine glands in the neck, usually located behind the thyroid gland. They produce parathyroid hormone, which helps raise the concentration of calcium in the blood. The glands maintain the body's calcium level within a very narrow range, so that the nervous and muscular systems can function properly. When the blood calcium levels drop below a certain point, calcium-sensing receptors in the parathyroid gland are activated to release the hormone into the blood.

In patients with APS-1, the parathyroid glands can be knocked out at a very young age. This can lead to severe cramp attacks caused by the calcium imbalance, which are often hard to treat using regular treatment. If the disease is not discovered it can possibly lead to death. This new discovery is expected to allow an early diagnosis of the condition, so that young sufferers can receive the proper treatment.

The fact that the protein NALP5 was found in the parathyroid glands is expected to provide scientists with a more complete understanding of the function of these glands. In addition, the latest discovery increases the possibility of developing drugs and methods of treatment for those diseases which produce a calcium imbalance, for example osteoporosis.

The fact that the protein functions as a target for the immune cells in humans, but also in animal models with the same genetic defect, is good news for further research into the disease. "This means now, for the first time, in an experimental situation we will be able to compare the immune defense with exactly the same target protein in humans and in an animal model," says Mohammad Ali Mohammadi at the Department of Medical Sciences, Uppsala University, who made the discovery.

For further information, please visit:
http://apeced.net/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...